The presence of the complement cascade does not lead to neuronal cell death in primary hippocampal cultures

Brain Research Bulletin

Volumn 42, Issue 3, 1997, Pages 187-193

  Manelli, Arlene M ^a   Cadman, Evelyn D ^a   Shiosaki, Kazumi ^a   Puttfarcken, Pamela S ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Complement; Hippocampal neurons; Homologous restriction; Inflammation; Neurodegeneration

Indexed keywords

COMPLEMENT; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DEATH; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CYTOLYSIS; HIPPOCAMPUS; INFLAMMATION; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELL DEATH; CELLS, CULTURED; COMPLEMENT SYSTEM PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; HUMANS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031014149     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(96)00203-1     Document Type: Article

References (26)

1. Aisen P. S., Davis L. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am. J. Psychol. 151:1994;1105-1113.
2. Asghar S. S. Membrane regulators of complement activation and their aberrant expression in disease. Lab. Invest. 72:((3)):1995;254-271.
3. Brewer G. J., Torricelli J. R., Evege E. K., Price P. J. Optimized survival of hippocampal neurons in B27-supplemented neurobasal, a new serum-free medium combination. J. Neurosci. Res. 35:((5)):1993;567-576.
4. Eikelenboom P., Hack C. E., Rozenmuller J. M., Stam F. C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch (Cell Pathol.). 56:1989;259-262.
5. Garcia J. E., Nonner D., Ross D., Barrett J. N. Neurotoxic components in normal serum. Exp. Neurol. 118:1992;309-316.
6. Gasque P., Fontaine M., Morgan B. P. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol. 154:1995;4726-4733.
7. Gasque P., Ischenko A., Legoedec J., Mauger C., Schouft M.-T., Fontaine M. Expression of the complement classical pathway by human glioma in culture. J. Biol. Chem. 33:1993;25068-25074.
8. Houle J. J., Hoffmann E. M. Evidence for restriction to the ability of complement to lyse homologous erythrocytes. J. Immunol. 133:1984;403.
9. Johnson S. A., Lampert-Etchells M., Pasinetti G. M., Rozovsky I., Finch C. E. Complement mRNA in the mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning. Neurobiol. Aging. 13:1992;641-648.
10. Link H. Complement factors in multiple sclerosis. Acta Neurol. Scand. 48:1972;521-528.
11. Linscott W. D., Nishioka K. Components of guinea pig complement. II. Separation of serum fractions essential for immune hemolysis. J. Exp. Med. 118:1963;795-815.
12. Linscott W. D. An antigen density effect on the hemolytic efficiency of complement. J. Immunol. 104:1970;1307-1309.
13. McGeer P. L., McGeer E. G. Complement proteins and complement inhibitors in Alzheimer's disease. Res. Immunol. 142:1992;621-623.
14. Morgan B. P. Complement membrane attack on nucleated cells: Resistance, recovery and non-lethal effects. Biochem. J. 264:1989;1-14.
15. Morgan B. P. Physiology and pathophysiology of complement: Progress and trends. Crit. Rev. Clin. Lab. Sci. 32:((3)):1995;265-298.
16. Muller-Eberhard H. J. Chemistry and reaction mechanisms of complement. Dixon F. J., Kunkel H. G. Advances in immunology. 8:1968;1-80 Academic Press, New York.
17. Pasinetti G. M., Johnson S. A., Rozovsky I., Lampert-Etchells M., Morgan D. G., Gordon M. N., Morgan T. E., Willoughby D., Finch C. E. Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Exp. Neurol. 118:1992;117-125.
18. Rogers J., Cooper N. R., Webster S., Schultz J., McGeer P. L., Styren S. D., Civin W. H., Brachova L., Brad B., Ward P., Lieberburg I. Complement activation by beta-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 89:1992;10016-10020.
19. Sanders M. E., Koski C. L., Robbins D., Shin M. L., Frank M. M., Joiner K. A. Activated terminal complement component in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J. Immunol. 135:1986;4456-4457.
20. Schultz J., Schaller J., McKinley M., Bradt B., Cooper N., May P., Rogers J. Enhanced cytotoxicity of amyloid β -peptide by a complement dependent mechanism. Neurosci. Lett. 175:1994;99-102.
21. Seya T., Nagasawa S. Limited protolysis of the third component of human complement, C3, by heat treatment. J. Biochem. 89:1981;659-664.
22. Shen Y., Halperin J. A., Lee C.-M. Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res. 671:1995;282-292.
23. Takahashi K., Nagasawa S., Koyama J. Effect of C1-inhibitor, benzamidine, and heat-treatment on the hydrolytic activity of a subcomponent of the first component of human complement, C1s. Biochim. Biophys. Acta. 611:1980;196-204.
24. Walker D. G., Yasuhara O., Patston P. A., McGeer E. G., McGeer P. L. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res. 675:1995;75-82.
25. Wing M. G., Zajicek J., Seilly D. J., Comptson D. A. S., Lachmann P. J. Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59. Immunology. 76:1992;140-145.
26. Wren D. R., Noble M. Oligodendrocytes and oligodentrocyte/type 2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in the absence of antibody. Proc. Natl. Acad. Sci. USA. 86:1989;9025-9034.